Recruiting

Vanquish TherapyWater Vapor Ablation for Prostate Cancer: Long-Term Registry

Sponsor:

Francis Medical Inc.

Code:

NCT07455058

Conditions

Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Vanquish Therapy

Study Details

Brief summary:

The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).

Conditions

Prostate Cancer

Study ID

NCT07455058

Start date

Jun 5, 2026

Status verified date

Feb, 2026

Completion date

Jul 31, 2041

Anticipated

Primary completion date

Apr 30, 2041

Anticipated

Eligibility Criteria

Sex: Male

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.
Participant is willing and able to provide written informed consent.

Exclusion Criteria:

Contraindications per the Vanquish IFU
Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.

Study Design

Enrollment

2500 participants

Anticipated

Interventions and Outcome Measures

Arms

Vanquish Procedure Patients

Patients that have completed or will complete a Vanquish therapy and plan to continue their routine clinical care.

Interventions

Vanquish Therapy

The Francis Medical, Inc. Vanquish Water Vapor Ablation Device ("Vanquish" or "Vanquish System") is a transurethral thermal water vapor ablation device. The Vanquish System is designed ablate prostate tissue, while minimizing side effects.

Primary outcome measure

Primary Efficacy Outcome [ Time Frame: Through study completion, or up to 15 years. ]
Primary Safety Outcome [ Time Frame: Through study completion, or up to 15 years ]

Central Contacts and Locations

Central contacts

Sydney Cartie

6122866855 scartie@francismedical.com

Garrett Grenier

763-453-9404 ggrenier@francismedical.com

Locations

WK Advanced Urology Specialists

Recruiting

Bossier City, Louisiana, United States, 71111

Contacts

Ryan Wilkerson

318-212-7335 rwilkerson@wkhs.com

Principal Investigator:

Gerard Henry, MD

Minnesota Urology

Recruiting

Woodbury, Minnesota, United States, 55125

Contacts

Melissa Robb

651-999-6800 mrobb@mnurology.com

Principal Investigator:

Aaron Milbank, MD

The Urology Place, Inc.

Recruiting

San Antonio, Texas, United States, 78240

Contacts

Naveen Kella, MD

210-617-3670 nkella@theupi.com

Principal Investigator:

Naveen Kella, MD

Urology of Virginia

Recruiting

Virginia Beach, Virginia, United States, 23462

Contacts

Robert Given, MD

757-452-3461 rgiven@urologyofva.net

Principal Investigator:

Robert Given, MD

More Information

Sponsor

Francis Medical Inc.

Last update posted

Aug 18, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Francis Medical Inc. on 2026-08-18.